| abstract |
Neutralizing prolactin receptor antibody Mat3, and antigen-binding fragments, pharmaceutical compositions containing them, benign disorders and indications mediated by prolactin receptors such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and breast pain, lactation suppression , The treatment or prevention of benign prostatic hyperplasia, fibromatosis, hyper- and normal prolactinemia hair loss, and co-treatment in combination hormone therapy to inhibit mammary epithelial cell proliferation and their use to treat and prevent anti-estrogen-resistant breast cancer . The antibody blocks prolactin receptor mediated signaling. |